Table of Contents
Journal of Allergy
Volume 2011, Article ID 752098, 2 pages
http://dx.doi.org/10.1155/2011/752098
Case Report

An Atypical Cutaneous Reaction to Rivastigmine Transdermal Patch

1Department of Dermatology, Universitá di Roma “La Sapienza”, Viale del Policlinico, 155, 00161 Rome, Italy
2Department of Technology for Health, Dermatological Clinic, IRCCS Galeazzi Hospital, University of Milan, 20122 Milan, Italy

Received 2 November 2010; Accepted 15 December 2010

Academic Editor: William E. Berger

Copyright © 2011 T. Grieco et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. H. Sadowsky, A. Dengiz, J. T. Olin, B. Koumaras, X. Meng, and S. Brannan, “Switching from donepezil tablets to rivastigmine transdermal patch in Alzheimer's disease,” American Journal of Alzheimer's Disease and other Dementias, vol. 24, no. 3, pp. 267–275, 2009. View at Publisher · View at Google Scholar · View at PubMed
  2. B. Winblad, J. Cummings, and J. Cummings, “A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease'rivastigmine patch versus capsule,” International Journal of Geriatric Psychiatry, vol. 22, no. 5, pp. 456–467, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. G. T. Grossberg, C. Sadowsky, and J. T. Olin, “Rivastigmine transdermal system for the treatment of mild to moderate Alzheimer's disease,” International Journal of Clinical Practice, vol. 64, no. 5, pp. 651–660, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. G. Alva and J. L. Cummings, “Relative tolerability of Alzheimer's disease treatments,” Psychiatry, vol. 5, no. 11, pp. 27–36, 2008. View at Google Scholar · View at Scopus
  5. A. Kurz, M. Farlow, and G. Lefèvre, “Pharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer's disease: a review,” International Journal of Clinical Practice, vol. 63, no. 5, pp. 799–805, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. M. Makris, S. Koulouris, I. Koti, X. Aggelides, and D. Kalogeromitros, “Maculopapular eruption to rivastigmine's transdermal patch application and successful oral desensitization,” Allergy, vol. 65, no. 7, pp. 925–926, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. G. Lefèvre, G. Sedek, H. -L.A. Huang, M. Saltzman, M. Rosenberg, B. Kiese, and P. Fordham, “Pharmacokinetics of a rivastigmine transdermal patch formulation in healthy volunteers: relative effects of body site application,” Journal of Clinical Pharmacology, vol. 47, no. 4, pp. 471–478, 2007. View at Publisher · View at Google Scholar · View at PubMed